ArticlePLoS pathogens2022
Reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters.
Open access · goldAbstract read
In one paragraph
Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- SARS-CoV-2 variants: biology, pathogenicity, immunity and control.Nature reviews. Microbiology · 2026Review
- Increased pathogenicity and transmission of SARS-CoV-2 Omicron XBB.1.9 subvariants, including HK.3 and EG.5.1, relative to BA.2.Journal of virology · 2025Article
- Intranasal measles virus- and mumps virus-based SARS-CoV-2 vaccine candidates prevent SARS-CoV-2 infection and transmission.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- SARS-CoV-2 variants retain high airborne transmissibility by different strategies.Npj viruses · 2025Article
- Amino acid substitutions in NSP6 and NSP13 of SARS-CoV-2 contribute to superior virus growth at low temperatures.Journal of virology · 2025Article
- Pathogenesis and transmission of SARS-CoV-2 D614G, Alpha, Gamma, Delta, and Omicron variants in golden hamsters.Npj viruses · 2025Article
- Barcoded SARS-CoV-2 viruses define the impact of duration and route of exposure on the transmission bottleneck in a hamster model.Science advances · 2025Article
- Evolution of Omicron lineage towards increased fitness in the upper respiratory tract in the absence of severe lung pathology.Nature communications · 2025Article
- Mucosal immunization with ChAd-SARS-CoV-2-S prevents sequential transmission of SARS-CoV-2 to unvaccinated hamsters.Science advances · 2024Article
- Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models.Zoological research · 2024Review
- SARS-CoV-2 variant of concern fitness and adaptation in primary human airway epithelia.Cell reports · 2024Article
- Augmentation of Omicron BA.1 pathogenicity in hamsters using intratracheal inoculation.Npj viruses · 2024Article
- Article
- Virological characteristics of SARS-CoV-2 Omicron BA.5.2.48.Frontiers in immunology · 2024Article
- Design and validation of an exposure system for efficient inter-animal SARS-CoV-2 airborne transmission in Syrian hamsters.Microbiology spectrum · 2023Article
- An FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission.Nature communications · 2023Article
- Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters.Nature communications · 2023Article
- Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron variants in mice and hamsters.Journal of virology · 2023Article
- SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models.Journal of virology · 2023Article
- A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8.Nature communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Adrianus C M BoonDepartment of Medicine, Washington University School of Medicine in St. Louis, Missouri, United States of America.ORCID 0000-0002-4700-8224
Tamarand L DarlingDepartment of Medicine, Washington University School of Medicine in St. Louis, Missouri, United States of America.
Peter J HalfmannDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, United States of America.
John FranksDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Richard J WebbyDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.
Julia R PortLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.
Vincent J MunsterLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.
Michael S DiamondDepartment of Medicine, Washington University School of Medicine in St. Louis, Missouri, United States of America.
Yoshihiro KawaokaDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, United States of America.
Washington University in St. Louis · USNational Institutes of Health · USSt. Jude Children's Research Hospital · USUniversity of Wisconsin–Madison · USBeth Israel Deaconess Medical Center · US
Funding
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00016 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI WEBBY, RICHARD · 2021 to 2025
$91.4MNIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6MEmerging infections: surveillance, epidemiology and pathogenesisU01AI151810 · NIAID · WASHINGTON UNIVERSITY · PI Adrianus CM Boon, DAVID WANG · 2020 to 2026
$10.0MHuman antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0MNIAID NIH HHS 75N93021C00014NIAID NIH HHS 75N93021C00016NIAID NIH HHS HHSN272201400008CNIAID NIH HHS R01 AI157155NIAID NIH HHS U01 AI151810
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19SARS-CoV-2AnimalsCricetinaeMesocricetusRespiratory Aerosols and Droplets
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.